Clinical Trials List
2025-10-15 - 2032-12-31
Phase III
Recruiting6
ICD-10G20
Parkinson's disease
ICD-10G21.4
Vascular parkinsonism
ICD-9332.0
Paralysis agitans
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/08/20
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- CHUN-HWEI TAI 無
- Ruey-Meei Wu 無
- 林靜嫺 無
- 廖庭蔚 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Yu Ao 無
- 陳彥中 無
- Jui-Cheng Chen 無
- Hui-Chun Huang 無
- Chon-Haw Tsai 無
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Body weight within 40-110 kilograms (kg) (88-242 pounds [lbs]) and a body mass index within the range 18-34 kg/m2
Diagnosis of idiopathic PD based on Movement Disorder Society (MDS) criteria
Has received monotherapy treatment
An MDS-UPDRS Part IV score of 0 at screening and prior to randomization
Hoehn and Yahr (H&Y) Stage 1 or 2 off medication at screening and prior to randomization
Agreement to adhere to the contraception requirements
Exclusion Criteria
Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which contraception is required
Medical history indicating a parkinsonian syndrome other than idiopathic PD
Diagnosis of a significant neurologic disease other than PD
Chronic uncontrolled hypertension
The Estimated Number of Participants
-
Taiwan
60 participants
-
Global
900 participants
